[S02DA03, antipyrine, The risk or severity of bleeding can be increased when Antipyrine is combined with Sulfinpyrazone.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Sulfinpyrazone.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptokinase.]
[L01AD04, streptozocin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Streptozocin.]
[M04AX02, pegloticase, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Pegloticase.]
[J01EC01, sulfamethoxazole, The metabolism of Sulfamethoxazole can be decreased when combined with Sulfinpyrazone.]
[M01AB02, sulindac, The risk or severity of bleeding can be increased when Sulindac is combined with Sulfinpyrazone.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Sulfinpyrazone.]
[M01AX04, apazone, The risk or severity of bleeding can be increased when Azapropazone is combined with Sulfinpyrazone.]
[L01BB02, mercaptopurine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Sulfinpyrazone.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Sulfinpyrazone.]
[B01AE07, dabigatran etexilate, Sulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Sulfinpyrazone.]
[A04AD10, dronabinol, The metabolism of Dronabinol can be decreased when combined with Sulfinpyrazone.]
[L04AX02, thalidomide, The metabolism of Thalidomide can be decreased when combined with Sulfinpyrazone.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Sulfinpyrazone.]
[L01XX41, eribulin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be increased when combined with Sulfinpyrazone.]
[L01BB03, thioguanine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tioguanine.]
[B01AC05, ticlopidine, Ticlopidine may increase the antiplatelet activities of Sulfinpyrazone.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Sulfinpyrazone.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Sulfinpyrazone.]
[M02AA21, tolmetin, The risk or severity of bleeding can be increased when Tolmetin is combined with Sulfinpyrazone.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Sulfinpyrazone.]
[N06AF04, tranylcypromine, The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Sulfinpyrazone.]
[C01DX11, trapidil, Sulfinpyrazone may increase the antiplatelet activities of Trapidil.]
[N06AX05, trazodone, The risk or severity of bleeding can be increased when Trazodone is combined with Sulfinpyrazone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Sulfinpyrazone.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Trichlormethiazide.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Sulfinpyrazone.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Sulfinpyrazone.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Sulfinpyrazone.]
[J01FA08, troleandomycin, The metabolism of Sulfinpyrazone can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be increased when combined with Sulfinpyrazone.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Sulfinpyrazone.]
[A10BH05, linagliptin, The metabolism of Sulfinpyrazone can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Sulfinpyrazone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Sulfinpyrazone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Sulfinpyrazone.]
[B01AD04, urokinase, Sulfinpyrazone may increase the anticoagulant activities of Urokinase.]
[B01AF01, rivaroxaban, Sulfinpyrazone may increase the anticoagulant activities of Rivaroxaban.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Sulfinpyrazone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Sulfinpyrazone.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Sulfinpyrazone.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Sulfinpyrazone.]
[A11HA03, vitamin E, Vitamin E may increase the antiplatelet activities of Sulfinpyrazone.]
[B01AA03, warfarin, The metabolism of Warfarin can be increased when combined with Sulfinpyrazone.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Sulfinpyrazone.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Sulfinpyrazone.]
[J05AE02, indinavir, The metabolism of Sulfinpyrazone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Sulfinpyrazone.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Sulfinpyrazone.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Sulfinpyrazone.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Zafirlukast can be decreased when combined with Sulfinpyrazone.]
[N05AE04, ziprasidone, The metabolism of Sulfinpyrazone can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Sulfinpyrazone.]
[L04AA34, alemtuzumab, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alemtuzumab.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the antiplatelet activities of Sulfinpyrazone.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Sulfinpyrazone.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Sulfinpyrazone.]
[C07AB03, atenolol, Atenolol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L03AB11, peginterferon alfa-2a, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2a.]
[L01FA01, rituximab, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Rituximab.]
[J02AC03, voriconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Atropine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Sulfinpyrazone.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Sulfinpyrazone.]
[L01BC07, azacitidine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Azacitidine.]
[L01BC05, gemcitabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemcitabine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Sulfinpyrazone.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Gemtuzumab ozogamicin.]
[L01XG02, carfilzomib, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Sulfinpyrazone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Sulfinpyrazone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Sulfinpyrazone.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Defibrotide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Sulfinpyrazone.]
[J05AE04, nelfinavir, The metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bendamustine.]
[N04BD02, rasagiline, The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Sulfinpyrazone.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Sulfinpyrazone.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Sulfinpyrazone.]
[L04AA29, tofacitinib, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tofacitinib.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Sulfinpyrazone.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Sulfinpyrazone.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Sulfinpyrazone.]
[B01AF02, apixaban, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Sulfinpyrazone.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Sulfinpyrazone.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Sulfinpyrazone.]
[N02BA10, benorilate, The risk or severity of bleeding can be increased when Benorilate is combined with Sulfinpyrazone.]
[M04AB03, benzbromarone, Sulfinpyrazone may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of bleeding can be increased when Celecoxib is combined with Sulfinpyrazone.]
[L04AA18, everolimus, The metabolism of Everolimus can be increased when combined with Sulfinpyrazone.]
[L01EC02, dabrafenib, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of bleeding can be increased when Benzydamine is combined with Sulfinpyrazone.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Sulfinpyrazone.]
[A05AA03, cholic acid, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Cholic Acid.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulfinpyrazone.]
[N06AX26, vortioxetine, The risk or severity of bleeding can be increased when Vortioxetine is combined with Sulfinpyrazone.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Sulfinpyrazone.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Sulfinpyrazone.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Sulfinpyrazone.]
[A16AA07, metreleptin, The metabolism of Sulfinpyrazone can be increased when combined with Metreleptin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Argatroban.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be increased when combined with Sulfinpyrazone.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be increased when combined with Sulfinpyrazone.]
[L01XH04, belinostat, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Sulfinpyrazone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Sulfinpyrazone.]
[L03AB13, peginterferon beta-1a, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Sulfinpyrazone.]
[L01BC08, decitabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Decitabine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Sulfinpyrazone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Sulfinpyrazone.]
[L01FX07, blinatumomab, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Blinatumomab.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Sulfinpyrazone.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Edoxaban.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Sulfinpyrazone.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Sulfinpyrazone.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Sulfinpyrazone.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Sulfinpyrazone.]
[M02AA25, aceclofenac, The risk or severity of bleeding can be increased when Aceclofenac is combined with Sulfinpyrazone.]
[M01AB11, acemetacin, Sulfinpyrazone may decrease the excretion rate of Acemetacin which could result in a higher serum level.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Sulfinpyrazone.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Sulfinpyrazone.]
[J02AC05, isavuconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Sulfinpyrazone.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Sulfinpyrazone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Sulfinpyrazone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Sulfinpyrazone.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Sulfinpyrazone.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Sulfinpyrazone.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Sulfinpyrazone.]
[M01AE16, alminoprofen, The risk or severity of bleeding can be increased when Alminoprofen is combined with Sulfinpyrazone.]
[N02BA02, aloxiprin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aloxiprin.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Sulfinpyrazone.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Sulfinpyrazone.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Sulfinpyrazone.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Sulfinpyrazone.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Obeticholic acid.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Sulfinpyrazone.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Sulfinpyrazone.]
[L01XX27, arsenic trioxide, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Sulfinpyrazone.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Sulfinpyrazone.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be increased when combined with Sulfinpyrazone.]
[L01EF02, ribociclib, The metabolism of Sulfinpyrazone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of bleeding can be increased when Balsalazide is combined with Sulfinpyrazone.]
[J01XX08, linezolid, The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Sulfinpyrazone.]
[J05AE09, tipranavir, Tipranavir may increase the antiplatelet activities of Sulfinpyrazone.]
[L01EX10, midostaurin, The metabolism of Sulfinpyrazone can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Sulfinpyrazone.]
[N04BD03, safinamide, The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Sulfinpyrazone.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Betrixaban.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Sulfinpyrazone.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Sulfinpyrazone.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Sulfinpyrazone.]
[L01XH01, vorinostat, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Sulfinpyrazone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Sulfinpyrazone.]
[J05AG03, efavirenz, The metabolism of Sulfinpyrazone can be decreased when combined with Efavirenz.]
[L01BA03, raltitrexed, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Raltitrexed.]
[R03BA02, budesonide, Sulfinpyrazone may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Sulfinpyrazone may increase the antiplatelet activities of Buflomedil.]
[M01AB07, bumadizone, The risk or severity of bleeding can be increased when Bumadizone is combined with Sulfinpyrazone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Sulfinpyrazone.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Sulfinpyrazone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Sulfinpyrazone.]
[L03AB06, interferon alfa-n1, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Sulfinpyrazone.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Sulfinpyrazone.]
[L01XX62, ivosidenib, The metabolism of Sulfinpyrazone can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Sulfinpyrazone can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Sulfinpyrazone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Sulfinpyrazone.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Sulfinpyrazone.]
[M01AC05, lornoxicam, The risk or severity of bleeding can be increased when Lornoxicam is combined with Sulfinpyrazone.]
[L01AD01, carmustine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Carmustine.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Sulfinpyrazone.]
[B01AX07, caplacizumab, Sulfinpyrazone may increase the antiplatelet activities of Caplacizumab.]
[B01AC23, cilostazol, Sulfinpyrazone may increase the antiplatelet activities of Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Sulfinpyrazone.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Sulfinpyrazone.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Sulfinpyrazone can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Sulfinpyrazone.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Sulfinpyrazone.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Sulfinpyrazone.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Sulfinpyrazone.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Sulfinpyrazone.]
[N07XX11, pitolisant, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Sulfinpyrazone.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Sulfinpyrazone.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Sulfinpyrazone.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Cyclothiazide.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Sulfinpyrazone.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Sulfinpyrazone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Sulfinpyrazone.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Sulfinpyrazone.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Sulfinpyrazone.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Sulfinpyrazone.]
[N03AX25, cenobamate, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Cenobamate.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Sulfinpyrazone.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Sulfinpyrazone.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Sulfinpyrazone.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Sulfinpyrazone.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Sulfinpyrazone.]
[J05AE05, amprenavir, The metabolism of Sulfinpyrazone can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Sulfinpyrazone.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Sulfinpyrazone.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Sulfinpyrazone.]
[M01AH02, rofecoxib, The risk or severity of bleeding can be increased when Rofecoxib is combined with Sulfinpyrazone.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Sulfinpyrazone.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Sulfinpyrazone.]
[L01AA02, chlorambucil, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Chlorambucil.]
[S03AA08, chloramphenicol, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Sulfinpyrazone.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Sulfinpyrazone.]
[M01AC04, droxicam, The risk or severity of bleeding can be increased when Droxicam is combined with Sulfinpyrazone.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Sulfinpyrazone.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of bleeding can be increased when Dexketoprofen is combined with Sulfinpyrazone.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Sulfinpyrazone.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Sulfinpyrazone.]
[L01FX15, belantamab mafodotin, Sulfinpyrazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Sulfinpyrazone.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Sulfinpyrazone.]
[N02BA07, ethenzamide, The risk or severity of bleeding can be increased when Ethenzamide is combined with Sulfinpyrazone.]
[N02BA03, choline salicylate, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Choline salicylate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Sulfinpyrazone.]
[M01AB08, etodolac, The risk or severity of bleeding can be increased when Etodolac is combined with Sulfinpyrazone.]
[M02AA06, etofenamate, The risk or severity of bleeding can be increased when Etofenamate is combined with Sulfinpyrazone.]
[B06AC06, berotralstat, The metabolism of Sulfinpyrazone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Sulfinpyrazone can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fludarabine.]
[P03AX07, abametapir, The serum concentration of Sulfinpyrazone can be increased when it is combined with Abametapir.]
[M01AE05, fenbufen, The risk or severity of bleeding can be increased when Fenbufen is combined with Sulfinpyrazone.]
[S01JA01, fluorescein, Fluorescein may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Sulfinpyrazone.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Sulfinpyrazone.]
[L03AB10, peginterferon alfa-2b, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Sulfinpyrazone.]
[L01XX73, sotorasib, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Sulfinpyrazone.]
[S03AA07, ciprofloxacin, The metabolism of Sulfinpyrazone can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of hemorrhage can be increased when Citalopram is combined with Sulfinpyrazone.]
[M01AG01, mefenamic acid, The risk or severity of bleeding can be increased when Mefenamic acid is combined with Sulfinpyrazone.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Sulfinpyrazone.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Sulfinpyrazone.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Sulfinpyrazone.]
[N06AX25, St. John's wort extract, The metabolism of Sulfinpyrazone can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The risk or severity of bleeding and thrombocytopenia can be increased when Sulfinpyrazone is combined with Abrocitinib.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tenecteplase.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Sulfinpyrazone.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Sulfinpyrazone.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Sulfinpyrazone.]
[C01EB24, mavacamten, The serum concentration of Sulfinpyrazone can be decreased when it is combined with Mavacamten.]
[A05BA08, glycyrrhizic acid, Sulfinpyrazone may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Sulfinpyrazone.]
[N05AH02, clozapine, The metabolism of Sulfinpyrazone can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Sulfinpyrazone can be increased when combined with Somatrogon.]
[M01AX13, proquazone, The risk or severity of bleeding can be increased when Proquazone is combined with Sulfinpyrazone.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Sulfinpyrazone.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Sulfinpyrazone.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of bleeding can be increased when Imidazole salicylate is combined with Sulfinpyrazone.]
[L01BB07, nelarabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Sulfinpyrazone can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Sulfinpyrazone.]
[M01AH03, valdecoxib, The risk or severity of bleeding can be increased when Valdecoxib is combined with Sulfinpyrazone.]
[M01AH04, parecoxib, The risk or severity of bleeding can be increased when Parecoxib is combined with Sulfinpyrazone.]
[J02AC02, itraconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bemiparin.]
[M01AA06, kebuzone, The risk or severity of bleeding can be increased when Kebuzone is combined with Sulfinpyrazone.]
[L01EA01, imatinib, The metabolism of Imatinib can be decreased when combined with Sulfinpyrazone.]
[J02AC04, posaconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Posaconazole.]
[M01AB09, lonazolac, The risk or severity of bleeding can be increased when Lonazolac is combined with Sulfinpyrazone.]
[R06AX13, loratadine, Loratadine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of bleeding can be increased when Loxoprofen is combined with Sulfinpyrazone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Cyclopenthiazide.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Sulfinpyrazone.]
[N06AX07, minaprine, The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Sulfinpyrazone.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.]
[N06AG02, moclobemide, The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Sulfinpyrazone.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Sulfinpyrazone.]
[M02AA02, mofebutazone, The risk or severity of bleeding can be increased when Mofebutazone is combined with Sulfinpyrazone.]
[M01AX22, morniflumate, The risk or severity of bleeding can be increased when Morniflumate is combined with Sulfinpyrazone.]
[C03XA02, conivaptan, The metabolism of Sulfinpyrazone can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of bleeding can be increased when Etoricoxib is combined with Sulfinpyrazone.]
[L01AX04, dacarbazine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Sulfinpyrazone can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Sulfinpyrazone.]
[L01DB02, daunorubicin, Daunorubicin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Sulfinpyrazone.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal irritation can be increased when Sulfinpyrazone is combined with Nabumetone.]
[N06AX06, nefazodone, The metabolism of Sulfinpyrazone can be decreased when combined with Nefazodone.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Sulfinpyrazone.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of bleeding can be increased when Escitalopram is combined with Sulfinpyrazone.]
[A07EC03, olsalazine, The risk or severity of bleeding can be increased when Olsalazine is combined with Sulfinpyrazone.]
[L01XA03, oxaliplatin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of bleeding can be increased when Oxaprozin is combined with Sulfinpyrazone.]
[S03BA01, dexamethasone, The metabolism of Sulfinpyrazone can be increased when combined with Dexamethasone.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Sulfinpyrazone.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Sulfinpyrazone.]
[N06AB05, paroxetine, The risk or severity of hemorrhage can be increased when Paroxetine is combined with Sulfinpyrazone.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Sulfinpyrazone.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Sulfinpyrazone.]
[S01BC03, diclofenac, The risk or severity of bleeding can be increased when Diclofenac is combined with Sulfinpyrazone.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be increased when combined with Sulfinpyrazone.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Sulfinpyrazone.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[C08CA03, isradipine, The metabolism of Sulfinpyrazone can be decreased when combined with Isradipine.]
[N02BA11, diflunisal, The risk or severity of bleeding can be increased when Diflunisal is combined with Sulfinpyrazone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be increased when combined with Sulfinpyrazone.]
[C01AA05, digoxin, Digoxin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[C10AX09, ezetimibe, Ezetimibe may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Sulfinpyrazone may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Sulfinpyrazone.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Sulfinpyrazone.]
[L04AX04, lenalidomide, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lenalidomide.]
[J05AE08, atazanavir, The metabolism of Sulfinpyrazone can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Treprostinil may increase the antiplatelet activities of Sulfinpyrazone.]
[C08DB01, diltiazem, The metabolism of Sulfinpyrazone can be decreased when combined with Diltiazem.]
[N02BB04, propyphenazone, The risk or severity of bleeding can be increased when Propyphenazone is combined with Sulfinpyrazone.]
[M01AB14, proglumetacin, The risk or severity of bleeding can be increased when Proglumetacin is combined with Sulfinpyrazone.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Sulfinpyrazone.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Sulfinpyrazone.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Sulfinpyrazone.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be increased when combined with Sulfinpyrazone.]
[P03AA04, disulfiram, Disulfiram may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Sulfinpyrazone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Sulfinpyrazone can be increased when combined with Rifapentine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be increased when combined with Sulfinpyrazone.]
[A04AD12, aprepitant, The metabolism of Sulfinpyrazone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Sulfinpyrazone.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Sulfinpyrazone.]
[S01BC05, ketorolac, The risk or severity of bleeding can be increased when Ketorolac is combined with Sulfinpyrazone.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Sulfinpyrazone.]
[N02BA06, salsalate, The risk or severity of bleeding can be increased when Salsalate is combined with Sulfinpyrazone.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Sulfinpyrazone.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Sulfinpyrazone.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Sertraline is combined with Sulfinpyrazone.]
[A08AA10, sibutramine, The risk or severity of hemorrhage can be increased when Sibutramine is combined with Sulfinpyrazone.]
[C10AA01, simvastatin, Simvastatin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01AX03, temozolomide, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of bleeding can be increased when Tenoxicam is combined with Sulfinpyrazone.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Sulfinpyrazone.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Sulfinpyrazone.]
[M01AG02, tolfenamic acid, The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Sulfinpyrazone.]
[N06AG03, toloxatone, The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Sulfinpyrazone.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Sulfinpyrazone.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Triflusal.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Troxerutin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Sulfinpyrazone.]
[N06AX16, venlafaxine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Sulfinpyrazone can be decreased when combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Epirubicin.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Sulfinpyrazone.]
[M01AB04, zomepirac, The risk or severity of bleeding can be increased when Zomepirac is combined with Sulfinpyrazone.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Sulfinpyrazone.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Carboplatin.]
[B01AC11, iloprost, Iloprost may increase the antiplatelet activities of Sulfinpyrazone.]
[N02CA02, ergotamine, The metabolism of Sulfinpyrazone can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Valproic acid can be decreased when combined with Sulfinpyrazone.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Sulfinpyrazone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Sulfinpyrazone.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M01AC06, meloxicam, The risk or severity of bleeding can be increased when Meloxicam is combined with Sulfinpyrazone.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Sulfinpyrazone.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be increased when combined with Sulfinpyrazone.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Sulfinpyrazone.]
[R06AX12, terfenadine, The metabolism of Sulfinpyrazone can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Sulfinpyrazone.]
[N06AB08, fluvoxamine, The metabolism of Sulfinpyrazone can be decreased when combined with Fluvoxamine.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Deoxycholic acid.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dextran.]
[V03AF02, dexrazoxane, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dexrazoxane.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Sulfinpyrazone.]
[C08CA02, felodipine, Felodipine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M01AE04, fenoprofen, The risk or severity of bleeding can be increased when Fenoprofen is combined with Sulfinpyrazone.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cladribine.]
[N02BG04, floctafenine, The risk or severity of bleeding can be increased when Floctafenine is combined with Sulfinpyrazone.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Flucytosine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Sulfinpyrazone.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Sulfinpyrazone.]
[L01BC09, floxuridine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Floxuridine.]
[L01BC02, fluorouracil, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fluorouracil.]
[N06AB03, fluoxetine, The metabolism of Fluoxetine can be decreased when combined with Sulfinpyrazone.]
[S01BC04, flurbiprofen, The risk or severity of bleeding can be increased when Flurbiprofen is combined with Sulfinpyrazone.]
[G01AX06, furazolidone, The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Sulfinpyrazone.]
[J05AE10, darunavir, The metabolism of Sulfinpyrazone can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Sulfinpyrazone.]
[L01EA02, dasatinib, Dasatinib may increase the anticoagulant activities of Sulfinpyrazone.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Sulfinpyrazone.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Sulfinpyrazone.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Sulfinpyrazone.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Sulfinpyrazone.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Sulfinpyrazone.]
[M01AX05, glucosamine, Glucosamine may increase the antiplatelet activities of Sulfinpyrazone.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Sulfinpyrazone.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Sulfinpyrazone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Sulfinpyrazone.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Fluindione.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Sulfinpyrazone.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Sulfinpyrazone.]
[M04AA01, allopurinol, The excretion of Sulfinpyrazone can be increased when combined with Allopurinol.]
[C09CA01, losartan, The metabolism of Losartan can be decreased when combined with Sulfinpyrazone.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Sulfinpyrazone.]
[A07EC02, mesalamine, The risk or severity of bleeding can be increased when Mesalazine is combined with Sulfinpyrazone.]
[L01XX03, altretamine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Altretamine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Sulfinpyrazone.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Sulfinpyrazone.]
[C08CA10, nilvadipine, The metabolism of Sulfinpyrazone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Sulfinpyrazone.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Hydroflumethiazide.]
[L01XX05, hydroxyurea, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Hydroxyurea.]
[R02AX02, ibuprofen, The risk or severity of bleeding can be increased when Ibuprofen is combined with Sulfinpyrazone.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Sulfinpyrazone.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Sulfinpyrazone.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Sulfinpyrazone.]
[L01CE01, topotecan, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of bleeding can be increased when Indomethacin is combined with Sulfinpyrazone.]
[L03AB04, interferon alfa-2a, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Sulfinpyrazone.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Sulfinpyrazone.]
[C10AA06, cerivastatin, Cerivastatin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01XX35, anagrelide, Anagrelide may increase the antiplatelet activities of Sulfinpyrazone.]
[L03AB09, interferon alfacon-1, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon alfacon-1.]
[N06AF05, iproniazid, The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Sulfinpyrazone.]
[N06AF01, isocarboxazid, The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Sulfinpyrazone.]
[J04AC01, isoniazid, The metabolism of Sulfinpyrazone can be decreased when combined with Isoniazid.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Bivalirudin.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Sulfinpyrazone.]
[C02KD01, ketanserin, Sulfinpyrazone may increase the antiplatelet activities of Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The risk or severity of bleeding can be increased when Ketoprofen is combined with Sulfinpyrazone.]
[M01AE11, tiaprofenic acid, The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Sulfinpyrazone.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Sulfinpyrazone.]
[A05AA02, ursodiol, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Ursodeoxycholic acid.]
[L01DC03, mitomycin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Mitomycin.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Sulfinpyrazone.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Sulfinpyrazone.]
[L01AD02, lomustine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Sulfinpyrazone can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Sulfinpyrazone.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be increased when combined with Sulfinpyrazone.]
[L01EA03, nilotinib, The metabolism of Sulfinpyrazone can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Sulfinpyrazone.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dalteparin.]
[L01AA03, melphalan, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Melphalan.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Sulfinpyrazone.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Sulfinpyrazone.]
[N07BC02, methadone, The metabolism of Methadone can be decreased when combined with Sulfinpyrazone.]
[H03BB02, methimazole, The metabolism of Sulfinpyrazone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Pemetrexed.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Sulfinpyrazone.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Sulfinpyrazone.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Methyclothiazide.]
[V04CG05, methylene blue, The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Sulfinpyrazone.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Sulfinpyrazone.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Sulfinpyrazone.]
[S02AA13, miconazole, The metabolism of Sulfinpyrazone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of bleeding can be increased when Aminophenazone is combined with Sulfinpyrazone.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Parnaparin.]
[G03XB01, mifepristone, Mifepristone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Tinzaparin.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Sulfinpyrazone.]
[L01XX23, mitotane, The metabolism of Sulfinpyrazone can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Sulfinpyrazone.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Sulfinpyrazone.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be increased when combined with Sulfinpyrazone.]
[L03AB08, interferon beta-1b, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Interferon beta-1b.]
[V03AB15, naloxone, The metabolism of Sulfinpyrazone can be decreased when combined with Naloxone.]
[M02AA12, naproxen, The risk or severity of bleeding can be increased when Naproxen is combined with Sulfinpyrazone.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[N06AX21, duloxetine, The metabolism of Duloxetine can be decreased when combined with Sulfinpyrazone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Sulfinpyrazone.]
[A10BX02, repaglinide, Repaglinide may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[B01AC17, tirofiban, Tirofiban may increase the antiplatelet activities of Sulfinpyrazone.]
[N06AX23, desvenlafaxine, The metabolism of Sulfinpyrazone can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Amsacrine.]
[N06AF02, nialamide, The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Sulfinpyrazone.]
[C08CA04, nicardipine, The metabolism of Sulfinpyrazone can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Sulfinpyrazone.]
[C08CA05, nifedipine, Nifedipine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of bleeding can be increased when Niflumic acid is combined with Sulfinpyrazone.]
[C08CA08, nitrendipine, Nitrendipine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The serum concentration of Nitrofurantoin can be increased when it is combined with Sulfinpyrazone.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Sulfinpyrazone.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Sulfinpyrazone.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Sulfinpyrazone.]
[B01AC16, eptifibatide, Eptifibatide may increase the antiplatelet activities of Sulfinpyrazone.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reviparin.]
[S02AA16, ofloxacin, Sulfinpyrazone may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Sulfinpyrazone.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Ancrod.]
[S01BC02, oxyphenbutazone, The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Sulfinpyrazone.]
[J04AA01, aminosalicylic acid, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aminosalicylic acid.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Danaparoid.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Sulfinpyrazone.]
[C02KC01, pargyline, The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Sulfinpyrazone.]
[M01CC01, penicillamine, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Penicillamine.]
[N05CA01, pentobarbital, The metabolism of Sulfinpyrazone can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Pentostatin.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the antiplatelet activities of Sulfinpyrazone.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Sulfinpyrazone.]
[N06AF03, phenelzine, The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Sulfinpyrazone.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Phenobarbital can be decreased when combined with Sulfinpyrazone.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The risk or severity of bleeding can be increased when Phenylbutazone is combined with Sulfinpyrazone.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Sulfinpyrazone.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Sulfinpyrazone.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Sulfinpyrazone.]
[C10AA05, atorvastatin, Atorvastatin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Sulfinpyrazone can be decreased when combined with Saquinavir.]
[S01BC06, piroxicam, The risk or severity of bleeding can be increased when Piroxicam is combined with Sulfinpyrazone.]
[J05AG02, delavirdine, The metabolism of Sulfinpyrazone can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Sulfinpyrazone.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Alteplase.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Sulfinpyrazone.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Sulfinpyrazone.]
[C03AA05, polythiazide, The therapeutic efficacy of Sulfinpyrazone can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Sulfinpyrazone can be increased when it is combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Sulfinpyrazone.]
[P01BA03, primaquine, The metabolism of Sulfinpyrazone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Sulfinpyrazone can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Sulfinpyrazone.]
[L01XB01, procarbazine, The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Sulfinpyrazone.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[N05AA03, promazine, The metabolism of Promazine can be decreased when combined with Sulfinpyrazone.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Sulfinpyrazone.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Sulfinpyrazone.]
[H03BA02, propylthiouracil, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Propylthiouracil.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Sulfinpyrazone.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Sulfinpyrazone.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Sulfinpyrazone.]
[P01BC01, quinine, The metabolism of Quinine can be decreased when combined with Sulfinpyrazone.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Sulfinpyrazone can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of bleeding can be increased when Salicylamide is combined with Sulfinpyrazone.]
[A07EC01, sulfasalazine, The risk or severity of bleeding can be increased when Sulfasalazine is combined with Sulfinpyrazone.]
[S01BC08, salicylic acid, The risk or severity of bleeding can be increased when Salicylic acid is combined with Sulfinpyrazone.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Sulfinpyrazone.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Obinutuzumab.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Sulfinpyrazone.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
